Zsuzsanna Pápai

Pseudomyogenic hemangioendothelioma (involving skin, bone and soft tissue): a case report with long-term follow-up and review of literature

Maysam Moghaddam Amin, Ákos Sükösd, Imre Antal, Zoltán Sápi et autres

INTRODUCTION: Pseudomyogenic hemangioendothelioma is rare, usually indolent vascular tumor characterized immunohistochemically by SERPINE1-FOSB fusion, presenting as multiple bone and soft tissue lesions, affecting males in their 3rd-4th decades. CASE PRESENTATION: We present the case of a 28-years-old male patient with the history …

hu (code pays fourni par la source)

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

R. Dent, Rebecca Dent, Z. Shao, P. Schmid et autres

BACKGROUND: Prognosis is poor, and treatment options are limited for patients with previously untreated, advanced triple-negative breast cancer (TNBC), especially for those who are not candidates for immunotherapy. PATIENTS AND METHODS: In the randomised, open-label, phase III TROPION-Breast02 trial, patients with previously …

sg, cn, gb, ch, ca, jp, kr, fr, mx, tr, es, Afrique du Sud, tw, hu, it, us, ar, pl, nl (code pays fourni par la source)

Intratumoral Radioenhancer Nanoparticle NBTXR3 Followed by Radiotherapy in Head and Neck Cancer

Christophe Le Tourneau, Xavier Liem, France Nguyen, Simon Deraedt et autres

Importance: Intratumoral delivery of NBTXR3 radioenhancer followed by radiation therapy (RT) previously demonstrated safety and feasibility in cisplatin-ineligible and cetuximab-ineligible patients with locally advanced head and neck squamous cell carcinoma (HNSCC) in a dose-escalation phase 1 study. Objective: To evaluate safety and …

fr, es, pl, us, gb, lu, hu (code pays fourni par la source)

Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18

Graham Cohen, Corlia Coetzee, Òscar Reig, Byoung Chul Cho et autres

Afrique du Sud, us, es, kr, gb, hu, jp, cl (code pays fourni par la source)

Microtracer‐Based Assessment of the Mass Balance, Pharmacokinetics, and Excretion of [14C]Berzosertib, an Intravenous ATR Inhibitor, in Patients With Advanced Solid Tumors: A Phase 1 Study

Jayaprakasam Bolleddula, Holger Scheible, Florian Huber, Annick Seithel‐Keuth et autres

Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 …

us, de, hu (code pays fourni par la source)

Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors

Òscar Reig, Graham Cohen, Byoung Chul Cho, Carlos A. Rojas et autres

Abstract Background: Pembrolizumab is approved for treatment of multiple cancers as an intravenous (IV) infusion. Subcutaneous (SC) administration offers more convenience and flexibility in the clinic. We report results of the phase 1, open-label, 3475A-C18 study (NCT05017012) of MK-3475A (pembrolizumab with berahyaluronidase …

es, Afrique du Sud, kr, ie, hu, us (code pays fourni par la source)

Real-world experience with pazopanib in locally advanced and metastatic soft tissue sarcomas: a Hungarian retrospective single-center study

Nóra Ecker, Marietta Aranyi, É Kiss, Nóra Kiss et autres

Pazopanib is a tyrosine-kinase inhibitor also used for the treatment of advanced soft tissue sarcomas. Our retrospective study analyzed real-world data of stage 4 sarcoma patients treated with pazopanib in our department in the past 10 years. Data were collected from the …

nl, hu (code pays fourni par la source)

417P Final and exploratory results of a phase I trial evaluating novel radioenhancer NBTXR3 activated by radiotherapy in cisplatin-ineligible LA HNSCC patients

C. Le Tourneau, X. Liem, Tuan V. Nguyen, Sophie El Bedoui et autres

fr, es, lu, hu, pl (code pays fourni par la source)

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib

Jayesh Desai, Andrew J. Wagner, Irene Carrasco García, Marilena Cesari et autres

BACKGROUND: Pexidartinib is effective in patients with tenosynovial giant cell tumor (TGCT) for whom surgery is not feasible. Durability of response after discontinuation of pexidartinib and the safety and efficacy of restarting pexidartinib have not been previously recorded. This phase 4 study …

au, us, es, it, tw, hu, nl (code pays fourni par la source)

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas et autres

PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with …

us, kr, es, it, cn, ca, jp, tw, br, fr (code pays fourni par la source)

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

Kristoffer Staal Rohrberg, Zsuzsanna Pápai, Rikke Løvendahl Eefsen, Jeffrey Yachnin et autres

2641 Background: BI-1808 is an IgG1 mAb that target TNFR2 by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8+ T cells. Upon co-administration of murine surrogate antibodies targeting TNFR2 and anti-PD-1 to …

dk, hu, se, gb, us (code pays fourni par la source)

International guidelines for intratumoral and intranodal injection of NBTXR3 nanoparticles in head and neck cancers

X. Liem, Thierry de Baère, Omar I. Vivar, Tanguy Y. Seiwert et autres

BACKGROUND: An international multidisciplinary panel of experts aimed to provide consensus guidelines describing the optimal intratumoral and intranodal injection of NBTXR3 hafnium oxide nanoparticles in head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, and cervical lymph nodes and …

fr, us, pk, es, hu, ca, it (code pays fourni par la source)